PMCB
- PharmaCyte Biotech, Inc.
()
Overview
Company Summary
PharmaCyte Biotech, Inc. (PMCB) is a biotechnology company that focuses on developing targeted cellular therapies for the treatment of diseases such as cancer. The company's primary area of expertise lies in the utilization of its proprietary Cell-in-a-Box� technology platform.
Cell-in-a-Box� is an innovative encapsulation technology that enables the encapsulation of genetically modified cells in a specially designed, biocompatible, protective encapsulation device. These modified cells are engineered to carry out specific functions, such as producing therapeutic enzymes or delivering anti-cancer agents.
PharmaCyte Biotech aims to use this platform to develop therapies capable of fighting various types of cancer. The encapsulated cells function as "biological factories," continuously producing therapeutic enzymes or anti-cancer agents in a controlled and targeted manner, thereby minimizing potential side effects.
The company's flagship product under development is the treatment for pancreatic cancer, which is one of the deadliest forms of cancer with limited treatment options. PharmaCyte Biotech's therapy involves implanting the encapsulated modified cells directly into the patient's tumor to convert a prodrug into its active or toxic form, specifically targeting cancer cells while sparing healthy cells.
In addition to its work in pancreatic cancer, PharmaCyte Biotech is also exploring the potential applications of its Cell-in-a-Box� technology in other areas such as diabetes and other forms of cancer.
Overall, PharmaCyte Biotech, Inc. is dedicated to advancing innovative cellular therapies using its unique encapsulation technology to create targeted treatment options for various diseases, with a specific focus on cancer.